FDANonrulemakingFDA-2019-D-2733
Who commented on this docket
Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency; Immediately in Effect Guidance for Industry; Availability
1 organizations filed 1 public comment on Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency; Immediately in Effect Guidance for Industry; Availability, at the Food and Drug Administration.
Organizations
1
Comments
1
RIN
—
Comment window
—
Commenters (1)
- National Community Pharmacists Associationtrade assoc.1 filing · confidence 97%
Attribution is name-based and imperfect. regulations.gov data is public record.